JP2024518410A5 - - Google Patents
Info
- Publication number
- JP2024518410A5 JP2024518410A5 JP2023568333A JP2023568333A JP2024518410A5 JP 2024518410 A5 JP2024518410 A5 JP 2024518410A5 JP 2023568333 A JP2023568333 A JP 2023568333A JP 2023568333 A JP2023568333 A JP 2023568333A JP 2024518410 A5 JP2024518410 A5 JP 2024518410A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- dose
- pharmaceutical product
- approximately
- product according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163185613P | 2021-05-07 | 2021-05-07 | |
| US63/185,613 | 2021-05-07 | ||
| US202263303655P | 2022-01-27 | 2022-01-27 | |
| US63/303,655 | 2022-01-27 | ||
| PCT/US2022/028063 WO2022236047A1 (en) | 2021-05-07 | 2022-05-06 | Use of an anti-cd19 antibody to treat myasthenia gravis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024518410A JP2024518410A (ja) | 2024-05-01 |
| JP2024518410A5 true JP2024518410A5 (https=) | 2025-05-13 |
Family
ID=81846343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023568333A Pending JP2024518410A (ja) | 2021-05-07 | 2022-05-06 | 重症筋無力症を治療するための抗ｃｄ１９抗体の使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240270842A1 (https=) |
| EP (1) | EP4333987A1 (https=) |
| JP (1) | JP2024518410A (https=) |
| KR (1) | KR20240004367A (https=) |
| AU (1) | AU2022270697A1 (https=) |
| BR (1) | BR112023022133A2 (https=) |
| CA (1) | CA3217586A1 (https=) |
| IL (1) | IL308296A (https=) |
| MX (1) | MX2023012703A (https=) |
| WO (1) | WO2022236047A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024155810A1 (en) * | 2023-01-20 | 2024-07-25 | Viela Bio, Inc. | Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| DE69534530T2 (de) | 1994-08-12 | 2006-07-06 | Immunomedics, Inc. | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
| PT2281843T (pt) | 2000-06-16 | 2017-01-02 | Human Genome Sciences Inc | Anticorpos que se ligam imunoespecificamente a blys |
| BRPI0209933B8 (pt) | 2001-05-24 | 2021-05-25 | Zymogenetics Inc | proteína de fusão, e, molécula de ácido nucleico |
| BRPI0315295C1 (pt) | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
| JP2007526220A (ja) | 2003-06-05 | 2007-09-13 | ジェネンテック・インコーポレーテッド | Ｂ細胞疾患の併用療法 |
| DOP2006000029A (es) | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| RU2495882C2 (ru) | 2006-09-08 | 2013-10-20 | Медиммун, Ллк. | Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания |
| DK2211904T3 (en) * | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| CN102421800A (zh) * | 2009-02-23 | 2012-04-18 | 格兰马克药品股份有限公司 | 结合cd19的人源化抗体及其用途 |
| AU2015277516A1 (en) | 2014-06-16 | 2016-12-22 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (CLL) |
| EP3423491A1 (en) | 2016-03-01 | 2019-01-09 | H. Hoffnabb-La Roche Ag | Obinutuzumab variants having altered cell death induction |
| AU2020263418A1 (en) * | 2019-04-24 | 2021-11-11 | Viela Bio, Inc. | Use of an anti-CD19 antibody to treat autoimmune disease |
-
2022
- 2022-05-06 IL IL308296A patent/IL308296A/en unknown
- 2022-05-06 KR KR1020237036834A patent/KR20240004367A/ko active Pending
- 2022-05-06 BR BR112023022133A patent/BR112023022133A2/pt unknown
- 2022-05-06 EP EP22725660.9A patent/EP4333987A1/en active Pending
- 2022-05-06 MX MX2023012703A patent/MX2023012703A/es unknown
- 2022-05-06 US US18/559,195 patent/US20240270842A1/en active Pending
- 2022-05-06 WO PCT/US2022/028063 patent/WO2022236047A1/en not_active Ceased
- 2022-05-06 JP JP2023568333A patent/JP2024518410A/ja active Pending
- 2022-05-06 CA CA3217586A patent/CA3217586A1/en active Pending
- 2022-05-06 AU AU2022270697A patent/AU2022270697A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Letko et al. | Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy | |
| Sabatelli et al. | Pure motor chronic inflammatory demyelinating polyneuropathy | |
| JP6250728B2 (ja) | α−２Ｂアドレナリン受容体作動薬を用いて制御性Ｔ細胞を活性化する方法 | |
| Burek-Michalska et al. | Adalimumab in the treatment of non-infectious uveitis | |
| US20210163955A1 (en) | Endomucin inhibitor as an anti-angiogenic agent | |
| JP2024178420A (ja) | 多発性硬化症を治療するためのｌｏｕ０６４ | |
| Wroblewski et al. | Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease | |
| JP2024518410A5 (https=) | ||
| Rommer et al. | Repurposing multiple sclerosis drugs: a review of studies in neurological and psychiatric conditions | |
| TW202342099A (zh) | 醫藥組合物 | |
| JP2023536944A (ja) | 疾患の治療におけるｂｔｋ阻害剤の使用 | |
| Nowak et al. | The position of monoclonal antibodies and small molecules in the treatment of thyroid orbitopathy | |
| JP7186214B2 (ja) | 自己免疫性神経筋疾患を処置するためのクラドリビンの使用 | |
| Zanon-Moreno et al. | New horizons for the treatment of glaucoma. I: Neuroinflammation and inflammasomes | |
| US20170035735A1 (en) | Use Of Enoximone In The Treatment Of Atopic Immune-Related Disorders, In Pharmaceutical Composition As Well As In Pharmaceutical Preparation | |
| US20240270842A1 (en) | Use of an anti-cd19 antibody to treat myasthenia gravis | |
| Ugradar et al. | The Use of Biologics for Thyroid Eye Disease: S. Ugradar et al. | |
| US20210322422A1 (en) | Use of akt inhibitors in ophthalmology | |
| Pazzola et al. | Biologics in vasculitides: Where do we stand, where do we go from now? | |
| KR20180050410A (ko) | 항-CD20 및 항-BLyS 항체의 조합물의 투여양생법 | |
| Gul et al. | Safe, Rapid-Onset, and Sustained Biological Activity of IL-1beta Regulating Antibody XOMA 052 in Resistant Uveitis of Behçet’s Disease: Preliminary Results of a Pilot Trial | |
| Khim | Myasthenia gravis treatment | |
| Akkus et al. | Recent treatment guidelines and approach toward autoimmune encephalitis | |
| Hasiri et al. | Intra-vitreal injection of methotrexate in experimental endotoxin-induced uveitis in rabbit | |
| Sullivan et al. | Emerging therapeutic strategies for asthma management |